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Abstract
Background: Liver biopsy is a widely used, safe diagnostic tool utilised by clinicians for the histopathological assess-
ment of the liver. Our study aims to report our experience in patients who underwent ultrasound-guided plugged 
percutaneous liver biopsy in a tertiary care hospital in India.
Material and methods: The Institutional Ethical Review Board approved this retrospective study, and informed consent 
was obtained from all the patients. A total of 830 liver biopsies were performed between January 2014 and December 
2018, of which 782 were plugged percutaneous liver biopsies. The tract was plugged using Gelfoam slurry. Various 
observations related to the procedures were recorded. 
Results: Seven hundred and eighty-two were plugged percutaneous liver biopsies, which were performed during 
the study period. Of the 782 patients, 163 were male, and 619 were female (20.8 % and 79.2 %, respectively), with 
a mean age of 49.6 ± 2 years (1 month to 86 years). A 100% technical success rate was seen. No immediate major 
complications were documented in any of the patients who underwent plugged biopsies. No significant complications 
were seen in any patient.
Conclusions: Percutaneous liver biopsy is an extensively performed diagnostic tool. We found that ultrasound-guided 
percutaneous plugged liver biopsy is an easy to perform procedure, which is associated with a lower risk of a bleeding 
complications.
Key words: liver, biopsy, ultrasound, Gelfoam embolisation.
Correspondence address: 
Dr. Soumil Singhal, New Cross Hospital, Wolverhampton, United Kingdom, e-mail: drsoumilsinghal75@gmail.com 
Authors’ contribution: 
A Study design ∙ B Data collection ∙ C Statistical analysis ∙ D Data interpretation ∙ E Manuscript preparation ∙ F Literature search ∙ G Funds collection
Introduction
Liver biopsy is a widely used, safe diagnostic tool used by 
clinicians for the histopathological assessment of the liver. 
The procedure is associated with low morbidity (0.2%) and 
mortality (0.01%), and hence is considered relatively safe 
[1,2]. The first reported case of a liver biopsy performed 
for a diagnostic purpose dates back to 1923 [3]. The pro-
cedure has evolved over the last 70 years and has become 
an important tool in the clinician’s armamentarium. A liver 
biopsy can be performed either via the percutaneous route 
or via the transjugular route. Severe haemorrhage is the 
most common complication, which can occur secondarily 
to a hepatic artery or portal vein injury. Altered coagulation 
status is prevalent in patients with liver disease, increasing 
the risk of post-procedure bleeding complications. McGill 
et al., in a study comprising 9212 liver biopsies, found that 
0.11% of patients presented with fatal procedure-related 
bleeding complications and 0.24% presented with non-fatal 
bleeding. In patients with ascites and coagulopathy, trans-
jugular liver biopsy has been found be a safer option [4].
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Transjugular liver biopsy (TJLB) is an invasive proce-
dure that requires an internal jugular vein access. Trans-
jugular liver biopsy, when compared to percutaneous liver 
biopsy, yields small sample sizes with the fragmentation 
of samples when compared to the samples via the per-
cutaneous route. Because of its simplicity and high yield 
of tissue samples, percutaneous liver biopsy is the widely 
preferred procedure. A modification in the procedure was 
introduced to avoid the potential risk of bleeding, which 
was referred to as plugged liver biopsy (PLB).
PLB was first described in 1984 as a modification 
of the standard percutaneous biopsy [5,6]. Ultrasound-
guided percutaneous plugged liver biopsy is performed 
in patients with coagulopathy when TJLB is not available. 
The procedure is performed like any other conventional 
percutaneous liver biopsy until the sample has been ac-
quired. Following the acquisition of the sample, Gelfoam 
slurry/Gelfoam torpedo is injected via the co-axial needle.
Gelfoam, which is an embolic material, prevents 
post-biopsy bleeding through the capsular puncture site. 
Ultrasound-guided PLB is easy to perform, is less time 
consuming, and is associated with a lower risk of bleeding 
[7]. Our study aims to present a tertiary care experience 
in patients who underwent ultrasound-guided plugged 
percutaneous liver biopsy.
Material and methods
A retrospective study was performed in 830 patients who 
underwent liver biopsy in the Intervention Radiology 
Department of our institution (Gleneagles Global Hos-
pital-Bangalore & Chennai) between January 2014 and 
December 2018. Approval from the Institutional Review 
Board was obtained. The patients were identified using 
the hospital’s RIS (Radiology Information System), and 
their details were obtained. Details of the clinical indi-
cations of the procedure, histopathological reports, and 
post-procedural events, including complications, were 
reviewed in our study.
Patient preparation and diagnostic workup
All our patients were given an explanation about liver 
biopsy in detail, its indications, its associated complica-
tions, and alternative options, following which informed 
consent was obtained. Initial pre-procedural workup, 
which includes various laboratory investigations such as 
complete blood count (CBC), prothrombin time (PT), 
international normalized ratio (INR), and serology, were 
performed and reviewed before the procedure. All prior 
radiological investigations conducted were reviewed. 
Screening ultrasound was performed in all patients to 
plan the procedure. Patients on aspirin continued to take 
their medication. Clopidogrel was withheld for 5 days be-
fore the procedure. Patients who were on dual platelets 
were asked to discontinue clopidogrel for 5 days but con-
tinued to take their aspirin as usual. Patients who were 
on low molecular weight heparin were asked to withhold 
one dose before the procedure. Warfarin was withheld 
for 5 days and the patient was started on low-molecular-
weight heparin. A correction was given in patients when 
the INR value was more than 1.5 and the platelet count 
was less than 50,000 platelets per microlitre of blood. 
Patients with deranged INR were transfused with 10 to 
15 ml/kg of fresh frozen plasma immediately prior to the 
procedure.  Patients were transfused either a unit of single 
donor platelet or about 4 units of random donor platelets 
for correction.
Screening ultrasound
All screening ultrasound was performed on a GE LOGIQ 7 
(Waukesha, WI, US) or Mindray M7 (Shenzhen Mindray 
Biomedical Electronics Co. Ltd., Shenzhen, China) ultra-
sound machine using a 1-5 MHZ convex transducer to 
evaluate the biopsy site. The possibility of any anatomi-
cal variation (for example, Chilaiditi syndrome, in which 
a bowel loop lies between the abdominal wall and liver) 
was ruled out to avoid inadvertent puncture of adjacent 
viscus. Screening ultrasound also permitted the detec-
tion of focal lesions (which may or may not have been 
previously suspected). Ultrasound scan guidance helps in 
achieving the best biopsy sample rate.
Biopsy technique
The convex transducer is prepared using all sterile asep-
tic precautions. Initially, local anaesthetization of the 
skin and subcutaneous tissue was performed by injecting 
2% lignocaine (without adrenaline) using a 26 gauge (26 G) 
needle. The needle is further advanced under ultrasound 
guidance anaesthetizing up to the pericapsular region, 
and infiltration can be seen in the form of indentation 
of the liver capsule on real-time ultrasound. A small skin 
incision was made. An 18 G × 10/16 cm BARD co-axial 
(Mission semi-automatic system, Tempe, AZ) and Cook 
(Bloomington, IN, USA) core biopsy instrument was used 
for the procedure. The co-axial needle was advanced un-
der ultrasound guidance to avoid any significant vascular 
or critical structures in the chosen path. Once the tip of 
the co-axial needle was positioned following the capsu-
lar puncture into the region of interest, 3 or 4 cores were 
acquired. The liver capsule was penetrated only once to 
avoid the risk of bleeding. The grossly examined sample 
was carefully transferred into a container filled with for-
malin. An 18 mm tissue sample was considered full length 
when a 20 mm needle throw was performed.
Plugging of the needle tract
Following the biopsy, the needle tract was plugged using 
Gelfoam slurry. Gelatine sponge slurry was prepared by 
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cutting the sheet into a tiny pledget, which was placed 
in one of the syringes. The other syringe was filled with 
5 ml of normal saline and connected with the first using 
a 3-way stopcock. Using the Tessari technique, the pled-
gets were macerated into a thick slurry-like consistency. 
This temporary embolic preparation was injected into the 
needle tract via the co-axial needle by slowly withdrawing 
the sheath up to the capsular surface.
Post-procedure care
A tight compression bandage is applied at the biopsy site, 
and the patient is placed in a right decubitus position. 
Daycare patients are kept under observation for 4 hours, 
while inpatients are discharged after 1 day of observation. 
Post-procedural complications, if there are any, are looked 
for and documented as per the Society of Interventional 
Radiology guidelines [7]. Some patients complained of 
mild pain in the right shoulder region post-biopsy, which 
subsided after taking analgesics.
Results
During a 5-year period we performed a total of 830 liver 
biopsies, of which 48 were TJLBs. Hence, a total of 782 
plugged percutaneous liver biopsies were performed dur-
ing the study period. Of the 782 patients, 163 were male 
and 619 were female (20.8% and 79.2%, respectively) with 
a mean age of 49.6 ± 2 years and a median age of 53 years 
(1 month to 86 years). Five hundred and fifty (70.27%) 
biopsies were non-targeted while the remaining 232 (29.7%) 
were targeted lesion biopsies. Being a large transplant unit, 
the main indication of a non-targeted liver biopsy was to 
rule out a diffuse parenchymal disease, whereas targeted 
lesion biopsies were performed to achieve a definitive di-
agnosis. Segment VI of the liver was considered as the 
first site for non-targeted biopsy. Cases with ascites fluid 
were drained before performing a biopsy. Left segment 
II was considered in cases when right perihepatic fluid 
could not be drained completely and there was availability 
of a safe acoustic window around left segment II. Eighty-
three per cent of the biopsies were taken from the right 
lobe of the liver. Targeted biopsy was performed on lesions 
ranging from 1.0 to 12.8 cm (mean 3.8 cm). Lesions were 
normally approached by passing through normal liver 
parenchyma to avoid bleeding complications. In cases of 
multiple lesions, those without necrosis and those in the 
right lobes were considered as primary targets. In the case 
of necrotic lesions, biopsy was mainly performed from the 
wall for better histopathological yield.
In our cohort we came across several lesions adjacent 
to large vessels in a technically challenging site; in these 
cases we either chose another lesion if available or aimed 
at approaching the lesion on an axis parallel to the vessel. 
We also used a 20 G needle with a 10 mm throw to avoid 
any inadvertent vascular injury. 
Figure 1. Local anaesthetization of the skin and subcutaneous tissue under ultrasound guidance. Black arrow shows the needle tip on the subcutaneous plane 
Figure 2. 18 G × 16 cm semi-automatic system BARD co-axial (Mission, 
Tempe, AZ) 
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All the biopsies were technically successful in obtaining 
a histopathological diagnosis because of an adequate sam-
ple. The number of needle passes ranged from 1 to 4, with 
a mean of 2 ± 0.7. Mean sample length was about 18 mm, 
which included an average of 8.6 portal tracts.
Post procedure, all patients were observed for 4 hours. 
Patients who developed pain, hypotension, localised ten-
derness, or abdominal tenderness were re-evaluated with 
an ultrasound. Any presence of free fluid in the perihepat-
ic region prompted a 24-hour observation of the patient 
and a repeat complete blood count. If no fluid was noted, 
conservative management was implemented. Forty-three 
per cent of patients reported minor complications in the 
form of pain or discomfort in the right hypochondriac 
region or the right shoulder region, which settled on con-
servative management (including reassurance and using 
analgesics). After settlement of the patients’ complaints, 
a repeat assessment of vitals was made and patients were 
discharged with a guideline to immediately attend the ca-
sualty department in case of an emergency. Twenty-nine 
patients demonstrated some free fluid requiring a 24-hour 
observation; none of them needed any further manage-
ment. No repeat biopsies were performed in any patient. 
No immediate major complication was documented in 
any of the patients who underwent plugged percutaneous 
liver biopsies. The technical success of PLB was 100% in 
our study.
Our observation during the study revealed a diverse 
spectrum of patients who were referred for percutaneous 
liver biopsy. The spectrum included patients who were 
suspicious of chronic liver disease, patients with bleeding 
tendencies, for pre-transplant workup, post-liver trans-
plant, and those suspected of primary malignancy or 
metastasis. Patients with bleeding tendencies were given 
adequate correction before the procedure. One hundred 
and thirty-four patients (17.1%) had INR values over 1.5, 
and platelet counts less than 50,000 platelets per micro-
litre of blood, for which correction was given before the 
procedure. 
The largest subgroup of patients in our study was the 
post-liver transplant group. One hundred and thirty pa-
tients (16.6%) were diagnosed to have graft rejection, and 
10 patients (1.3%) were diagnosed to have post-transplant 
hepatitis and sepsis, respectively. Two patients (0.25%) 
had features of tuberculosis, and five (0.64%) post-trans-
plant patients had normal liver parenchyma.
During the pre-transplant evaluation, 32 (4.1%) pa-
tients showed features of steatosis, and 8 (1.02%) patients 
showed non-alcoholic steatohepatitis features. Thirteen 
patients (1.66%) had normal donor liver parenchyma.
Figure 4. Tessari technique: procedure performed to make Gelfoam slurry 
Figure 3. Sequential images showing an ultrasound guided plugged liver biopsy, co-axial needle (yellow arrow) positioned, followed by acquisition of liver 
tissue and plugging of tract using Gelfoam slurry 
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Thirteen samples demonstrated features of steatosis. 
Fibrosis was seen in 99 patients, of whom 5 had non- 
cirrhotic portal fibrosis. One hundred and fifty-two pa-
tients showed features of hepatitis, of whom 12 (1.53%) 
were non-alcoholic steatohepatitis, 13 (1.63%) were au-
toimmune hepatitis, and 8 (1.02%) were secondary to 
hepatitis C. Fifteen patients showed features of chronic 
liver disease.
Targeted lesion biopsy revealed hepatocellular carci-
noma, cholangiocarcinoma, and metastasis in 48 (6.1%), 
40 (5.1%), and 111 (14.1%) patients, respectively. Hodg-
kin’s lymphoma, non-Hodgkin’s lymphoma, diffuse B-cell 
lymphoma, haemangioma, rhabdomyosarcoma, and undif-
ferentiated mesenchymal tumour were seen in 2 patients 
(0.25%) respectively. Other indications for the procedure 
included a) inflammation, b) Wilson’s disease, c) cholesta-
sis, d) infection, and e) obstructive cholangiopathy.
Gelfoam track embolization in our case series was 
found to be very effective in preventing major complica-
tions.
Discussion
Percutaneous liver biopsy is a gold standard technique 
used to acquire a tissue sample, which helps in facilitating 
the diagnosis [6-8]. Haemorrhage is the most common se-
rious complication associated with the procedure. Bleed-
ings are mainly secondary to arterial, portal, or intercostal 
arteries. A study that included 9212 liver biopsies found 
that 0.11% and 0.24% presented with fatal and non-fatal 
haemorrhage, respectively [9]. Post-biopsy bleeds are re-
lated to 3 factors: 1) patient-related, 2) technical causes, or 
3) lesion-associated causes. Patient-related factors include 
chronic liver disease, coagulopathy, thrombocytopaenia, 
platelet dysfunction, haematological malignancy, ascites, 
medications, or non-compliant patient [10-12].
Technical factors affecting the outcome include the 
number of cores acquired, the size of the needle used, non-
guided biopsies, and operator experience [13]. Lesion- 
related factors include the location of the lesion, its prox-
imity to major vascular structures, and its hyper-vascular 
nature. Transjugular liver biopsies have been advocated in 
the past as a reliable technique in patients with bleeding 
Table 1. Characteristics of percutaneous plugged liver biopsy procedures 





Total number of passes 1-4 (2 ± 0.7)
Mean sample length 18 mm
Average portal tract 8.6
Minor complications (pain, discomfort) 43%
Table 2. Indications for percutaneous plugged liver biopsy procedures
Diagnosis No. of patients Percentage (%)




Hepatocellular carcinoma 48 6.10
Cholangiocarcinoma 40 5.10
Donor liver steatosis 32 4.10
Inflammatory 31 3.96
Normal liver 23 3.00
Cholestasis 13 1.66
Autoimmune hepatitis 13 1.66
Donor normal liver 13 1.66
NASH (non-alcoholic steatohepatitis) 12 1.53
Cirrhosis 10 1.30
Steatosis 10 1.30
Transplant liver hepatitis 10 1.30
Transplant liver sepsis 10 1.30
Donor liver – NASH (non-alcoholic 
steatohepatitis)
8 1.02
Hepatitis C with recurrent fibrosis 8 1.02
Infection 8 1.02
Normal transplant liver 5 0.64
Wilson’s disease 5 0.64
NCPF (non-cirrhotic portal fibrosis) 5 0.64
Obstructive cholangiopathy 5 0.64
Chronic liver disease (CLD) 5 0.64
Hodgkin’s lymphoma 2 0.25
Non-Hodgkin’s lymphoma 2 0.25
Diffuse B-cell lymphoma 2 0.25






diathesis, poor respiration, and massive ascites [14,15]. 
However, TJLB has several drawbacks, including difficulty 
in acquiring biopsy from difficult sites (lesions away from 
a hepatic vein), inadequate sample acquisition, puncture 
site complications, arrhythmias, and haemoperitoneum 
[16-19]. TJLB is associated with large inter-operator vari-
ability and a steep learning curve, which can affect the out-
come of the procedure. A meta-analysis reviewing 7526 
TJLBs reported a technical failure rate of 3.2% [4]. Lebrec 
et al. reported intra-peritoneal haemorrhage as the most 
serious complication that occurs secondarily to capsular 
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tear [20]. Kalambokis et al. identified major and minor 
procedure-related complications in 0.2% and 3% of pa-
tients, respectively [4].
PLB was first described in 1984 by Riley et al. [5] 
as an alternative to the standard percutaneous biopsy. 
The procedure involved the post-biopsy embolization 
of the needle track in reducing the risk of haemorrhage. 
It is quicker, easier, and less time consuming as compared 
to TJLB. Gelfoam is most commonly used as an embolic 
agent. Gelfoam is an absorbable derivative of purified 
porcine skin. It acts by inducing a thrombus formation 
as well as providing structural integrity to the thrombus. 
It is widely used because it is readily available and cheap. 
Gelfoam is used in the form of either a torpedo or a slurry 
or both. Complications associated with the procedure in-
clude infection, biliary leak, biliary fistula, arterio-portal 
fistula, major bleeding, and death. Several small sample 
size studies have been conducted in the past, which have 
reported an overall success rate of 95% and a complication 
rate of less than 2% [6,14-16,21,22]. Sawyer et al. found no 
serious bleeding complications when PLB was performed 
in 100 patients with liver disease and coagulopathy [21].
Another study by Kamphuisen et al. in patients with 
chronic liver disease with coagulopathy found that PLB 
was technically successful and complication-free [16]. 
Our study reported no major post-biopsy haemorrhage; 
this finding was similar to those reported in the few previ-
ous studies [6,15,16].
Graft rejection is a significant concern in the post-
transplant liver, with biopsy playing a vital problem-solv-
ing role. Either TJLB or PLB can be performed in these 
cases. Azoulay et al. noted a 13% technical failure rate 
when TJLB was performed within 30 days of the post-
transplant period [23]. Risk of bleeding is high in the early 
post-transplant period, mainly due to thrombocytopae-
nia and ascites [4,7,23,24]. Park et al. reported the use of 
N-butyl cyanoacrylate as an alternative embolic agent for 
track embolization [25].
According to our literature search, our study is the 
most extensive series of plugged liver biopsy using Gel-
foam to date. We found that PLB was a safe and feasible 
technique to obtain a diagnosis in any clinical scenario, 
with a high level of confidence. Our findings are compa-
rable with those of all previously reported studies.
Our study had some limitations, including its retro-
spective study design; a case-control design would give 
more strength supporting plugged liver biopsy over con-
ventional percutaneous biopsy. Nevertheless, our study 
included a spectrum of conditions in which we used PLB 
over traditional percutaneous liver biopsy. A prospective 
case-control design is warranted for the same.
Conclusions
Percutaneous liver biopsy is an extensively performed di-
agnostic tool used in our everyday practice. However, it is 
associated with procedure-related bleeding complications. 
We found that ultrasound-guided percutaneous plugged 
liver biopsy is an easy to perform, less time-consuming 
procedure, which is associated with a lower risk of bleed-
ing complications.
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